<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000509174"><TermName>Oncaspar</TermName><TermPronunciation>(ON-kah-spar)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat acute lymphoblastic leukemia (ALL). It is a form of the drug asparaginase that is linked to a substance called PEG, which makes the drug stay in the body longer. Asparaginase is an enzyme that breaks down the amino acid asparagine and may block the growth of tumor cells that need asparagine to grow. It is a type of protein synthesis inhibitor. Also called PEG-asparaginase and pegaspargase.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000718572" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Oncaspar&quot;" language="en" id="_3"/><MediaLink ref="CDR0000718571" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Oncaspar&quot;" language="es" id="_4"/><SpanishTermName>Oncaspar</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para tratar la leucemia linfoblástica aguda (LLA). Es una forma del medicamento asparaginasa unido a una sustancia que se llama PEG, que permite que el medicamento permanezca en el cuerpo por más tiempo. La asparaginasa es una enzima que descompone el aminoácido asparagina y puede impedir la formación de las células tumorales que necesitan de la asparagina para crecer. Es un tipo de inhibidor de la síntesis de proteínas. También se llama PEG-asparaginasa y pegaspargasa.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2006-09-15</DateFirstPublished><DateLastModified>2009-03-13</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000506663">Pegaspargase</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
